4 Analysts Have This to Say About Inozyme Pharma
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 4 analysts have published bullish opinions on Inozyme Pharma (NASDAQ:INZY) stock, with an average 12-month price target of $19.5, an increase of 2.63% from the previous average price target of $19.00.
August 09, 2023 | 6:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Inozyme Pharma (NASDAQ:INZY) has received bullish ratings from 4 analysts over the past 3 months, with an average 12-month price target of $19.5, up 2.63% from the previous target.
The bullish ratings and increased price target indicate a positive outlook for Inozyme Pharma's stock in the short term. This could potentially lead to an increase in the stock's price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100